1-3 of 3
Yukang Lin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Steven I. Park, Jaideep Shenoi, Shani M. Frayo, Donald K. Hamlin, Yukang Lin, D. Scott Wilbur, Patrick S. Stayton, Nural Orgun, Mark Hylarides, Franz Buchegger, Aimee L. Kenoyer, Amanda Axtman, Ajay K. Gopal, Damian J. Green, John M. Pagel, Oliver W. Press
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7373–7382.
https://doi.org/10.1158/1078-0432.CCR-11-1204
Published: 30 November 2011
View articletitled, Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
Open the PDF for Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Pretargeted Radioimmunotherapy for B-Cell Lymphomas

Damian J. Green, John M. Pagel, Anastasia Pantelias, Nathan Hedin, Yukang Lin, D. Scott Wilbur, Ajay Gopal, Donald K. Hamlin, Oliver W. Press
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5598s–5603s.
https://doi.org/10.1158/1078-0432.CCR-07-1223
Published: 17 September 2007
View articletitled, Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Open the PDF for Pretargeted Radioimmunotherapy for B-Cell Lymphomas in another window
Journal Articles

Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy

Scott S. Graves, Erica Dearstyne, Yukang Lin, Yuting Zuo, James Sanderson, Jody Schultz, Anastasia Pantalias, David Gray, Don Axworthy, H. Mark Jones, Karen Auditore-Hargreaves
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3712–3721.
Published: 23 September 2003
View articletitled, Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy
Open the PDF for Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy in another window